Your browser doesn't support javascript.
loading
Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations.
Deschamps, Romain; Papeix, Caroline; Ayrignac, Xavier; Bourre, Bertrand; Ciron, Jonathan; Cohen, Mikael; Collongues, Nicolas; Deiva, Kumaran; Durand Dubief, Françoise; Laplaud, David-Axel; Maillart, Elisabeth; Michel, Laure; Pique, Julie; Ruet, Aurélie; Thouvenot, Eric; Zéphir, Hélène; Marignier, Romain; Audoin, Bertrand.
Afiliação
  • Deschamps R; Department of Neurology, hôpital Fondation Adolphe-de-Rothschild, Paris, France. Electronic address: rdeschamps@for.paris.
  • Papeix C; Department of Neurology, hôpital Fondation Adolphe-de-Rothschild, Paris, France.
  • Ayrignac X; Department of Neurology, University Hospital of Montpellier, Montpellier, France.
  • Bourre B; Department of Neurology, University Hospital of Rouen, Rouen, France.
  • Ciron J; Department of Neurology, University Hospital of Toulouse, Toulouse, France.
  • Cohen M; CRC-SEP neurologie Pasteur 2, CHU de Nice, université Cote d'Azur, UMR2CA (URRIS), Nice, France.
  • Collongues N; Department of Neurology and Department of Pharmacology, Addictology, Toxicology and Therapeutics, Center for Clinical Investigation, Inserm U1434, Biopathology of Myelin, Neuroprotection and Therapeutic Strategy, Inserm U1119, Strasbourg University, Strasbourg, France.
  • Deiva K; Department of Pediatric Neurology, Bicêtre Hospital, Assistance publique-Hôpitaux de Paris, University Hospitals Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Durand Dubief F; Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM), hôpital neurologique Pierre-Wertheimer, Lyon University Hospital, Lyon, France.
  • Laplaud DA; Department of Neurology, CR2TI-Inserm U1064, CIC1314, CHU de Nantes, Nantes université, Nantes, France.
  • Maillart E; Department of Neurology, centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM), hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
  • Michel L; Department of Neurology, Inserm UMR 1236, CHU de Rennes, université de Rennes 1, Rennes, France.
  • Pique J; Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM), hôpital neurologique Pierre-Wertheimer, Lyon University Hospital, Lyon, France.
  • Ruet A; Department of Neurology, University Hospital of Bordeaux, Bordeaux, France.
  • Thouvenot E; Department of Neurology, University Hospital of Nîmes, Nîmes, France.
  • Zéphir H; Department of Neurology, U 1172, CRC-SEP, University Hospital of Lille, Lille, France.
  • Marignier R; Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM), hôpital neurologique Pierre-Wertheimer, Lyon University Hospital, Lyon, France.
  • Audoin B; Department of Neurology, pôle de neurosciences cliniques, hôpital de la Timone, Marseille, AP-HM, Aix Marseille University, Marseille, France.
Rev Neurol (Paris) ; 2024 Jul 04.
Article em En | MEDLINE | ID: mdl-38969609
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article